Login
Asensus Surgical NYSE American: ASXC
Asensus Surgical, Inc., formerly TransEnterix, Inc., is a medical device company. The Company is engaged in digitizing the interface between the surgeon and the patient to improve minimally invasive surgery (MIS) through digital laparoscopy
| Name | Asensus Surgical |
| Ticker | ASXC |
| Exchange | NYSE American |
| Sector | Health Care |
| Industry | Medical Devices |
|
Price
52W Low/High |
2.10
0.31 / 6.32 |
| Momentum | Sharp Down |
| Market cap | 210 M |
| 1Y Total Return |
414.71%
Strong |
| 1Y Volatility |
169.11%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Asensus Surgical, Inc., formerly TransEnterix, Inc., is a medical device company. The Company is engaged in digitizing the interface between the surgeon and the patient to improve minimally invasive surgery (MIS) through digital laparoscopy
Details
| Ticker | ASXC |
| Name | Asensus Surgical |
| ISIN | US04367G1031 |
| CUSIP | 04367G103 |
| Exchange | NYSE American |
| Sector | Health Care |
| Industry | Medical Devices |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 4/13/21
| Close Price | 2.10 |
| 52W Low/High | 0.31 / 6.32 |
| Market cap | 210 M |
| 1Y Total Return |
414.71%
Strong |
| 1Y Volatility |
169.11%
High Risk |
| Beta | 3.41 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -1,890.5% |
| Cash from Op. / Cur. Liabilities | -4.54 |
| Diluted Earnings / Share | -0.85 |
| ROE | - |
| ROIC | -118.5% |
| Price / Revenue | 46.8 |
| Price / Book | 2.4 |
| Price / CF | -3.1 |
| Current Ratio | 3.3 |
| Cur.Liabilities / Tot.Liabilities | 0.6 |
| Financial Leverage | 0.05 |
| in Mils USD |
rolling-year up to December
|
|||||
|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
3
|
9
|
24
|
7
|
2
|
|
| Gross Profit |
-
|
-
|
8
|
0
|
0
|
|
| R&D |
17
|
22
|
22
|
22
|
29
|
|
| EBITDA |
-47
|
-140
|
-48
|
-135
|
-115
|
|
| Operating Income |
-57
|
-164
|
-50
|
-59
|
-123
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
|
| per Share | ||||||
| Diluted avg Shares |
71
|
18
|
16
|
11
|
9
|
|
| EPS exc. Extra |
-0.85
|
-8.69
|
-3.88
|
-12.61
|
-13.91
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
78
|
75
|
239
|
250
|
176
|
|
| Cash, Eq & Invt ShortTerm |
18
|
11
|
73
|
98
|
35
|
|
| Total Current Assets |
34
|
28
|
102
|
113
|
38
|
|
| Total Non-Current Assets |
44
|
47
|
138
|
137
|
138
|
|
| Intangibles |
22
|
29
|
120
|
124
|
106
|
|
| Total Liabilities |
17
|
19
|
71
|
71
|
58
|
|
| Total Current Liabilities |
10
|
13
|
22
|
29
|
31
|
|
| Long Term Debt |
6
|
6
|
49
|
43
|
28
|
|
| Shareholder equity |
62
|
56
|
169
|
179
|
118
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
-47
|
-73
|
-48
|
-47
|
-52
|
|
| Depreciation |
14
|
12
|
13
|
10
|
9
|
|
| Cash from Investing |
0
|
68
|
-53
|
6
|
-1
|
|
| Capex |
0
|
16
|
1
|
2
|
1
|
|
| Cash from Financing |
53
|
-6
|
26
|
104
|
50
|
|
| Stock Issued |
47
|
26
|
3
|
78
|
58
|
|
| Debt (LT) Issued |
3
|
-31
|
13
|
0
|
-7
|
|
| Free Cash Flow |
-49
|
-102
|
-116
|
-140
|
-104
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
3.3
|
2.1
|
4.7
|
3.9
|
1.2
|
|
| Financial Leverage D/E |
0.05
|
0.00
|
0.17
|
0.07
|
0.11
|
|
| Return on Capital Avg |
-118.5%
|
-117.7%
|
-37.3%
|
-120.8%
|
-75.3%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
|
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available